Introduction: Medicines with antimicrobial effects and preservatives that are part of some non- sterile drugs can inhibit the growth of certain types of microorganisms.[1,2] There are some test strains of microorganisms from different groups that are used to register this action like Gram-positive cocci, grampositive, spore-forming bacillus, Gram-negative enterobacteria, Pseudomonas, yeastlike fungi genus Candida [3,4,5].
Aim: Laboratory research of medicines "Angisept" and "Loringosept" antimicrobial activity in vitro in respect of specially selected strains of microorganism cultures.
Angisept (Loringosept) - complex antiseptic medicine for use in case of infectious and inflammatory diseases of the oral cavity and pharynx. It has antibacterial and anti-inflammatory action. Indications: acute and chronic upper respiratory tract infections (acute respiratory infections, bronchitis, tonsillitis, gingivitis, stomatitis); inflammatory diseases of the mouth and throat; ulcers and sores in the mouth; unpleasant sensations in the mouth and throat (dry and scratchy); bad breath.
Materials and methods. Commercial products "D.Angisept" (HC «Dentafill Plys» production, composition: propolis tincture - 0.06 g, ascorbic acid - 0.02 g) and "Loringosept" («Radiks» PShK production, composition: propolis tincture - 0.06 g, ascorbic acid - 0.02 g) were selected for investigation.
Studies were carried out according to the requirements of "Methods of microbiological control of medicines” (XI release 2 edition, pp. 187-225. M .; Health -1990) and "Guidelines for quality control of laboratory tests" (Tashkent, 2000). For the cultivation of microorganisms and testing of medicine samples methods given in SP XI were used.
Antimicrobial activity of the medicines was determined by the test cultures of microorganisms sensitivity by serial dilutions in a dense medium ("Determination of the sensitivity of microorganisms to antibacterial agents" MUK 4.2. RF 1890-04). The sensitivity of the test cultures was quantified by largest MIC (minimum inhibitory concentration), expressed in micrograms / ml.
The work involved 7 strains of microorganisms: S.aureus 004 134 \ ATCC 25923; E.faecalis 003 460 \ "CB"; E.faecium 002 768 \ 119; Bacillus subtilis 003 591 \ B-1; E.coli 004 136 \ ATCC 25922; Ps.aeruginosa 004 135 \ ATCC 27853; Candida albicans 003 848 \ 10.
Results. On the first step, comparative study of drugs was carried out by direct putting some tablets on the surface of a nutrient dense with the sowing of the test strains (semi-quantitative quality method). For further investigation microbial strains were selected by the serial dilution method (quantitative method), on which were rendered pronounced effect of the study drug. Studied series of drugs have a pronounced antimicrobial activity (MIC = 2,0-16 ug \ ml) on the test strains of Grampositive bacteria (S.aureus; E.faecalis; E.faecium; Bacillus subtilis vegetative form). On gram-negative bacteria (E.coli, Ps.aeruginosa) and yeast-like fungi of the genus Candida effect is negligible (MIC> 32.0 mg \ ml). MIC values of "Angisept" and "Loringosept" are not statistically different (p> 0.05). "D.Angisept" is comparable to the drug "Loringosept" according to its antimicrobial action.
Conclusion: Thus, studies found that gram-positive cocci are sensible to "Angisept" and "Loringosept" (composition: propolis tincture - 0.06 g ascorbic acid - 0.02 g). In respect to Gram-negative microorganisms and fungi Candida effects in vitro have not been identified.
Bibliography
- Malhotra N, Rao SP, Acharya S, Vasudev B.Comparative in vitro evaluation of efficacy of mouthrinses against Streptococcus mutans, Lactobacilli and Candida albicans.Oral health & preventive dentistry 2011;9(3):261-8.
- De Francisco L, Costa Y, Outuki PM, Souza RP, Bonfim-Mendonca PS, Novello CR, Consolaro M, Bruschi ML. Nanoparticles of waste material of propolis and gelatin as a novel system for delivery of L-ascorbic acid.Curr Drug Deliv. 2016 Mar 22. [Epub ahead of print]
- Raphael Richard Ciuman. Phytotherapeutic and naturopathic adjuvant therapiesin otorhinolaryngology. Eur Arch Otorhinolaryngol (2012) 269:389-397
- Sforcin JM, Bankova V. Propolis: is there a potential for the development of new drugs? J Ethnopharmacol. 2011; 133: 253-260.
- Demirkol G. Research of antimicrobial effects of propolis from province of Ordu. Sci Works Ser C VetMed. 2013; 1: 14-17.